Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
Saskia Räuber(Düsseldorf University Hospital), David Kremer(Heinrich Heine University Düsseldorf), Karin von Wnuck Lipinski(Heinrich Heine University Düsseldorf), Philipp Albrecht(Universitäts-Herzzentrum Freiburg-Bad Krozingen), Jens Ingwersen(Düsseldorf University Hospital), Melanie Korsen(Heinrich Heine University Düsseldorf), Christina B. Schroeter(University of Münster), Niklas Huntemann(Düsseldorf University Hospital), Bianca Teegen(Mayo Clinic), Sven G. Meuth(University Hospital Münster), Tristan Kölsche(Heinrich Heine University Düsseldorf), Liesa Regner-Nelke(Heinrich Heine University Düsseldorf), Orhan Aktaş(Heinrich Heine University Düsseldorf), Tobias Ruck(BG University Hospital Bergmannsheil Bochum), Christopher Nelke(Heinrich Heine University Düsseldorf), Hans‐Peter Hartung(The University of Sydney), Nico Melzer(Düsseldorf University Hospital), Marc Pawlitzki(Heinrich Heine University Düsseldorf), Michael Barnett(The University of Sydney), Leoni Rolfes(University Hospital Münster), Vera Dobelmann(Heinrich Heine University Düsseldorf), Alexander Hermann(Universitätszahnklinik Wien), Bodo Levkau(Düsseldorf University Hospital), Thomas Müntefering(Heinrich Heine University Düsseldorf)
Cited by 30
Related Papers
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k